AstraZeneca and Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive ...
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of ...
The British drugmaker lost roughly $27 billion in market value after Wainua failed to reduce cardiovascular deaths and recurring heart events ...
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to ...
The UK's FTSE 100 slipped on Thursday as investors grappled with renewed Middle East tensions, with heavyweight AstraZeneca ...
July 9 () - AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis, failed to meet the ...
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a ...
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
AstraZeneca sees stock market value slump by more than £20bn after drug setback - The FTSE 100 firm found the Wainua drug ...
AstraZeneca's stock tumbled after the pharmaceutical company said its Wainua drug failed to meet the primary target in a late-stage clinical trial for heart disease, denting investor hopes for ...
Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results